Nidipres (Lercanidipine Hydrochloride)

Lercanidipine Hydrochloride, the active ingredient in Nidipres, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adult patients with hypertension.

GNH USA supplies Nidipres as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker used to manage hypertension by relaxing arterial smooth muscle.

- Hypertension: reduces systolic and diastolic blood pressure in adults with primary hypertension. - Essential hypertension: helps achieve target blood pressure levels when lifestyle measures are insufficient. - High blood pressure: contributes to cardiovascular risk reduction as part of a comprehensive antihypertensive regimen.

Lercanidipine is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: especially upon standing. - Tachycardia: increased heart rate. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Nidipres, consider the following safety measures.

- Blood pressure monitoring: measure baseline and periodic readings to assess response. - Renal impairment: use cautiously in patients with severe kidney dysfunction. - Hepatic impairment: dose adjustment may be needed in moderate to severe liver disease. - Concomitant CYP3A4 inhibitors: avoid or monitor for increased drug exposure. - Pregnancy and lactation: safety not established; prescribe only if clearly needed. - Store at room temperature below 25°C: keep in the original pack, protect from moisture and light.

Lercanidipine may interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma levels and cause hypotension. - Grapefruit juice: may increase drug exposure leading to excessive blood pressure lowering. - Other antihypertensives (e.g., ACE inhibitors, ARBs): combined use may result in excessive blood pressure drop.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: concurrent use can increase risk of electrolyte imbalance. - Beta‑blockers: may mask tachycardia that signals low blood pressure.